{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:41:17Z","timestamp":1791549677684,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>CRISPR-Cas13a is renowned for its precise and potent RNA editing capabilities in cancer therapy. While various material systems have demonstrated efficacy in supporting CRISPR-Cas13a to execute cellular functions in vitro efficiently and specifically, the development of CRISPR-Cas13a-based therapeutic agents for intravesical instillation in bladder cancer (BCa) remains unexplored.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we introduce a CRISPR-Cas13a nanoplatform, which effectively inhibits PDL1 expression following intravesical instillation. This system utilizes a fusion protein CAST, created through the genetic fusion of CRISPR-Cas13 and the transmembrane peptide TAT. CAST acts as a potent transmembrane RNA editor and is assembled with the transepithelial delivery carrier fluorinated chitosan (FCS). Upon intravesical administration into the bladder, the CAST-crRNAa\/FCS nanoparticles (NPs) exhibit remarkable transepithelial capabilities, significantly suppressing PDL1 expression in tumor tissues.To augment immune activation within the tumor microenvironment, we integrated a fenbendazole (FBZ) intravesical system (FBZ@BSA\/FCS NPs). This system is formulated through BSA encapsulation followed by FCS coating, positioning FBZ as a powerful chemo-immunological agent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In an orthotropic BCa model, the FBZ@BSA\/FCS NPs demonstrated pronounced tumor cell apoptosis, synergistically reduced PDL1 expression, and restructured the immune microenvironment. This culminated in an enhanced synergistic intravesical instillation approach for BCa. Consequently, our study unveils a novel RNA editor nanoagent formulation and proposes a potential synergistic therapeutic strategy. This approach significantly bolsters therapeutic efficacy, holding promise for the clinical translation of CRISPR-Cas13-based cancer perfusion treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03146-0","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T02:02:29Z","timestamp":1723428149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy"],"prefix":"10.1186","volume":"43","author":[{"given":"Mingkang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"10061","key":"3146_CR1","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;388(10061):2796\u2013810.","journal-title":"Lancet"},{"issue":"1","key":"3146_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer Nat Rev Dis Primers. 2023;9(1):58.","journal-title":"Bladder cancer Nat Rev Dis Primers"},{"issue":"2","key":"3146_CR3","first-page":"283","volume":"9","author":"H Matsushima","year":"2002","unstructured":"Matsushima H, Kawabe K, Fujime M, Kitamura T, Homma Y, Kishi H, Kawamura T, Umeda T, Ohishi Y, Murai M, et al. Treatment of patients with superficial bladder cancer by intravesical instillation of anticancer drugs plus oral chemotherapy following TUR-Bt: a randomized controlled trial. Oncol Rep. 2002;9(2):283\u20138.","journal-title":"Oncol Rep"},{"key":"3146_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.urology.2018.10.028","volume":"124","author":"JT Rague","year":"2019","unstructured":"Rague JT, Lee RS. Management of High-grade, Nonmuscle Invasive Urothelial Carcinoma in a Prepubertal Patient With TURBT and Intravesical BCG. Urology. 2019;124:257\u20139.","journal-title":"Urology"},{"issue":"10","key":"3146_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276453","volume":"17","author":"W Zhou","year":"2022","unstructured":"Zhou W, Liu J, Mao D, Hu C, Gao D. The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis. PLoS ONE. 2022;17(10): e0276453.","journal-title":"PLoS ONE"},{"issue":"4","key":"3146_CR6","first-page":"426","volume":"71","author":"J Leon-Mata","year":"2018","unstructured":"Leon-Mata J, Dominguez JL, Redorta JP, Sousa Gonzalez D, Alvarez Casal M, Sousa Escandon A, Pineiro Vazquez E. Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. Arch Esp Urol. 2018;71(4):426\u201337.","journal-title":"Arch Esp Urol"},{"issue":"16","key":"3146_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/asia.202200342","volume":"17","author":"F Huo","year":"2022","unstructured":"Huo F, Zhang Y, Li Y, Bu H, Zhang Y, Li W, Guo Y, Wang L, Jia R, Huang T, et al. Mannose-targeting Concanavalin A-Epirubicin Conjugate for Targeted Intravesical Chemotherapy of Bladder Cancer. Chem Asian J. 2022;17(16): e202200342.","journal-title":"Chem Asian J"},{"issue":"1","key":"3146_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bju.15173","volume":"127","author":"A Elkashef","year":"2021","unstructured":"Elkashef A, Barakat N, Khater SM, Awadalla A, Belal F, El-Assmy AM, Sheir KZ, Shokeir AA. Effect of low-energy shock wave therapy on intravesical epirubicin delivery in a rat model of bladder cancer. BJU Int. 2021;127(1):80\u20139.","journal-title":"BJU Int"},{"issue":"6","key":"3146_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/2211-5463.13616","volume":"13","author":"H Yoshino","year":"2023","unstructured":"Yoshino H, Yokoyama S, Tamai M, Okamura S, Iizasa S, Sakaguchi T, Osako Y, Inoguchi S, Matsushita R, Yamada Y, et al. Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor. FEBS Open Bio. 2023;13(6):1056\u201366.","journal-title":"FEBS Open Bio"},{"issue":"18","key":"3146_CR10","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1080\/14656566.2023.2271396","volume":"24","author":"M Abou Chakra","year":"2023","unstructured":"Abou Chakra M, Packiam VT, O\u2019Donnell MA. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer. Expert Opin Pharmacother. 2023;24(18):2081\u201391.","journal-title":"Expert Opin Pharmacother"},{"key":"3146_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129: 110393.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3146_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14737140.2018.1421461","volume":"18","author":"N Sundahl","year":"2018","unstructured":"Sundahl N, Rottey S, De Maeseneer D, Ost P. Pembrolizumab for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2018;18(2):107\u201314.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"3146_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30814-3","volume":"19","author":"E Gourd","year":"2018","unstructured":"Gourd E. Neoadjuvant pembrolizumab in bladder cancer. Lancet Oncol. 2018;19(12): e669.","journal-title":"Lancet Oncol"},{"issue":"26","key":"3146_CR14","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3146_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30242-X","volume":"17","author":"V Brower","year":"2016","unstructured":"Brower V. Anti-PD-L1 inhibitor durvalumab in bladder cancer. Lancet Oncol. 2016;17(7): e275.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3146_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2217\/imt-2020-0261","volume":"13","author":"H Samaha","year":"2021","unstructured":"Samaha H, Samaha R, Sarkis J, Kattan J. Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy. Immunotherapy. 2021;13(4):271\u20135.","journal-title":"Immunotherapy"},{"key":"3146_CR17","doi-asserted-by":"publisher","first-page":"175628721882348","DOI":"10.1177\/1756287218823485","volume":"11","author":"A Rao","year":"2019","unstructured":"Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol. 2019;11:1756287218823485.","journal-title":"Ther Adv Urol"},{"issue":"8","key":"3146_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"3146_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737140.2023.2203385","volume":"23","author":"C Tholomier","year":"2023","unstructured":"Tholomier C, Martini A, Mokkapati S, Dinney CP. The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023;23(5):531\u201343.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"17","key":"3146_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2217\/fon-2020-0137","volume":"16","author":"SM Tham","year":"2020","unstructured":"Tham SM, Mahendran R, Chiong E, Wu QH, Esuvaranathan K. Gmcsf and Ifnalpha gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer. Future Oncol. 2020;16(17):1179\u201388.","journal-title":"Future Oncol"},{"issue":"10","key":"3146_CR21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","volume":"37","author":"JJ Duplisea","year":"2019","unstructured":"Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2019;37(10):2041\u20139.","journal-title":"World J Urol"},{"key":"3146_CR22","doi-asserted-by":"crossref","unstructured":"Moreo E, Uranga S, Pico A, Gomez AB, Nardelli-Haefliger D, Del Fresno C, Murillo I, Puentes E, Rodriguez E, Vales-Gomez M,\u00a0et al.\u00a0Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. J Immunother Cancer. 2022;10(7):e004325.","DOI":"10.1136\/jitc-2021-004325"},{"key":"3146_CR23","doi-asserted-by":"crossref","unstructured":"Zhang Y, Huo F, Cao Q, Jia R, Huang Q, Wang ZA, Theodorescu D, Lv Q, Li P, Yan C. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. J Immunother Cancer. 2022;10(3):e003939.","DOI":"10.1136\/jitc-2021-003939"},{"issue":"6499","key":"3146_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.abb6151","volume":"369","author":"AJ Meeske","year":"2020","unstructured":"Meeske AJ, Jia N, Cassel AK, Kozlova A, Liao J, Wiedmann M, Patel DJ, Marraffini LA. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity. Science. 2020;369(6499):54\u20139.","journal-title":"Science"},{"issue":"8","key":"3146_CR25","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.7150\/ijbs.33772","volume":"15","author":"F Qi","year":"2019","unstructured":"Qi F, Tan B, Ma F, Zhu B, Zhang L, Liu X, Li H, Yang J, Cheng B. A Synthetic Light-switchable System based on CRISPR Cas13a Regulates the Expression of LncRNA MALAT1 and Affects the Malignant Phenotype of Bladder Cancer Cells. Int J Biol Sci. 2019;15(8):1630\u20136.","journal-title":"Int J Biol Sci"},{"key":"3146_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.607740","volume":"7","author":"W Che","year":"2020","unstructured":"Che W, Ye S, Cai A, Cui X, Sun Y. CRISPR-Cas13a Targeting the Enhancer RNA-SMAD7e Inhibits Bladder Cancer Development Both in vitro and in vivo. Front Mol Biosci. 2020;7: 607740.","journal-title":"Front Mol Biosci"},{"issue":"51","key":"3146_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201905751","volume":"31","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Wang Q, Liu Q, Zheng Y, Zheng C, Yi K, Zhao Y, Gu Y, Wang Y, Wang C, et al. Dual-Locking Nanoparticles Disrupt the PD-1\/PD-L1 Pathway for Efficient Cancer Immunotherapy. Adv Mater. 2019;31(51): e1905751.","journal-title":"Adv Mater"},{"issue":"20","key":"3146_CR28","doi-asserted-by":"publisher","first-page":"eabn7382","DOI":"10.1126\/sciadv.abn7382","volume":"8","author":"N Fan","year":"2022","unstructured":"Fan N, Bian X, Li M, Chen J, Wu H, Peng Q, Bai H, Cheng W, Kong L, Ding S, et al. Hierarchical self-uncloaking CRISPR-Cas13a-customized RNA nanococoons for spatial-controlled genome editing and precise cancer therapy. Sci Adv. 2022;8(20):eabn7382.","journal-title":"Sci Adv"},{"issue":"4","key":"3146_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/cancers15041264","volume":"15","author":"V Cazzetta","year":"2023","unstructured":"Cazzetta V, Depierreux D, Colucci F, Mikulak J, Mavilio D. NKG2A Immune Checkpoint in Vdelta2 T Cells: Emerging Application in Cancer Immunotherapy. Cancers (Basel). 2023;15(4):1264.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"3146_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/imt-2016-0111","volume":"9","author":"MA Ali","year":"2017","unstructured":"Ali MA, Matboli M, Tarek M, Reda M, Kamal KM, Nouh M, Ashry AM, El-Bab AF, Mesalam HA, Shafei AE, et al. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy? Immunotherapy. 2017;9(1):99\u2013108.","journal-title":"Immunotherapy"},{"key":"3146_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2020.104930","volume":"68","author":"K Rudolf","year":"2020","unstructured":"Rudolf K, Rudolf E. An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole. Toxicol In Vitro. 2020;68: 104930.","journal-title":"Toxicol In Vitro"},{"key":"3146_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105305","volume":"164","author":"X Zhou","year":"2021","unstructured":"Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, Shu F, Tan X, Yang Y, Cen S, et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol Res. 2021;164: 105305.","journal-title":"Pharmacol Res"},{"key":"3146_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41420-017-0017-2","volume":"4","author":"X Zhou","year":"2018","unstructured":"Zhou X, Liu J, Zhang J, Wei Y, Li H. Flubendazole inhibits glioma proliferation by G2\/M cell cycle arrest and pro-apoptosis. Cell Death Discov. 2018;4:18.","journal-title":"Cell Death Discov"},{"issue":"18","key":"3146_CR34","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.7150\/thno.43473","volume":"10","author":"Y Zhen","year":"2020","unstructured":"Zhen Y, Zhao R, Wang M, Jiang X, Gao F, Fu L, Zhang L, Zhou XL. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer. Theranostics. 2020;10(18):8080\u201397.","journal-title":"Theranostics"},{"key":"3146_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.680600","volume":"9","author":"X Xie","year":"2021","unstructured":"Xie X, Cai X, Tang Y, Jiang C, Zhou F, Yang L, Liu Z, Wang L, Zhao H, Zhao C, et al. Flubendazole Elicits Antitumor Effects by Inhibiting STAT3 and Activating Autophagy in Non-small Cell Lung Cancer. Front Cell Dev Biol. 2021;9: 680600.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"3146_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/jphp.12503","volume":"68","author":"V Kralova","year":"2016","unstructured":"Kralova V, Hanusova V, Rudolf E, Canova K, Skalova L. Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro. J Pharm Pharmacol. 2016;68(2):208\u201318.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3146_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","volume":"38","author":"S Lin","year":"2019","unstructured":"Lin S, Yang L, Yao Y, Xu L, Xiang Y, Zhao H, Wang L, Zuo Z, Huang X, Zhao C. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J Exp Clin Cancer Res. 2019;38(1):293.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3146_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12967-023-04289-y","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Wu B, Hossain MJ, Quagliata L, O\u2019Meara C, Wilkins MR, Corley S, Khachigian LM. Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice. J Transl Med. 2023;21(1):467.","journal-title":"J Transl Med"},{"key":"3146_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.canlet.2019.05.026","volume":"459","author":"Y Li","year":"2019","unstructured":"Li Y, Acharya G, Elahy M, Xin H, Khachigian LM. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. Cancer Lett. 2019;459:268\u201376.","journal-title":"Cancer Lett"},{"issue":"5","key":"3146_CR40","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1021\/acsnano.2c09266","volume":"17","author":"W Zhu","year":"2023","unstructured":"Zhu W, Chao Y, Jin Q, Chen L, Shen JJ, Zhu J, Chai Y, Lu P, Yang N, Chen M, et al. Oral Delivery of Therapeutic Antibodies with a Transmucosal Polymeric Carrier. ACS Nano. 2023;17(5):4373\u201386.","journal-title":"ACS Nano"},{"issue":"2","key":"3146_CR41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1021\/acsnano.9b06689","volume":"14","author":"G Li","year":"2020","unstructured":"Li G, Wang S, Deng D, Xiao Z, Dong Z, Wang Z, Lei Q, Gao S, Huang G, Zhang E, et al. Fluorinated Chitosan To Enhance Transmucosal Delivery of Sonosensitizer-Conjugated Catalase for Sonodynamic Bladder Cancer Treatment Post-intravesical Instillation. ACS Nano. 2020;14(2):1586\u201399.","journal-title":"ACS Nano"},{"issue":"15","key":"3146_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209435120","volume":"120","author":"Q Ma","year":"2023","unstructured":"Ma Q, Jiang H, Ma L, Zhao G, Xu Q, Guo D, He N, Liu H, Meng Z, Liu J, et al. The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation. Proc Natl Acad Sci U S A. 2023;120(15): e2209435120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3146_CR43","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","volume":"34","author":"D Guo","year":"2022","unstructured":"Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, Wu Q, Li S, Luo S, Li M, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IkappaBalpha. Cell Metab. 2022;34(9):1312-1324 e1316.","journal-title":"Cell Metab"},{"issue":"3","key":"3146_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","volume":"23","author":"AT Ruffin","year":"2023","unstructured":"Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023;23(3):173\u201388.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03146-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T14:08:36Z","timestamp":1723471716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03146-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03146-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Female C57BL\/6 mice10\u201312\u00a0weeks old were purchased from Gempharmatech Co., Ltd and used following protocols approved by Research Ethics Committee of the Affiliated Luohu Hospital.of Shenzhen University (2023-LHQRMYY-KYLL-007).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}